Use of Neratinib in HER2-Positive Breast Cancer

Treatment Options for HER2+ Breast Cancer: A Comprehensive GuideПодробнее

Dr Davis on the Investigation of Neratinib + Trastuzumab Deruxtecan in Advanced HER2+ Solid TumorsПодробнее

Early-Stage HER2+ Breast Cancer: Become an Advocate in Your Care With NERLYNXПодробнее

ELEANOR: real-world study of extended adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

ELEANOR: observing real-life extended adjuvant therapy with neratinib and concurrent use of CONKADOПодробнее

Are You Worried About HER2+ Breast Cancer Recurrence?Подробнее

ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancerПодробнее

GS4 10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastaticПодробнее

Final results from the phase 2 SUMMIT basket trial: targeting HER2+ advanced BTCs with neratinibПодробнее

Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2 Breast CancerПодробнее

Brain metastases in HER2+ breast cancerПодробнее

Neratinib Plus Fulvestrant for HER2 Mutant, Non-Amplified Metastatic Breast CancerПодробнее

ELEANOR: real-world use of neratinib in HER2+, early breast cancerПодробнее

NERLYNX® (neratinib) Important Safety InformationПодробнее

Pyrotinib Plus Capecitabine for HER2 Metastatic Breast CancerПодробнее

Neratinib + fulvestrant + trastuzumab for HR+ HER2-mutant mBC and neratinib + trastuzumab for tr...Подробнее

Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast CancerПодробнее

Breast Cancer BCOP 2021Подробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее